Arcturus Therapeutics In...

10.21
0.78 (8.27%)
At close: Apr 02, 2025, 3:59 PM
9.99
-2.07%
After-hours: Apr 02, 2025, 07:55 PM EDT

Arcturus Therapeutics Statistics

Share Statistics

Arcturus Therapeutics has 27.12M shares outstanding. The number of shares has increased by 0.7% in one year.

Shares Outstanding 27.12M
Shares Change (YoY) 0.7%
Shares Change (QoQ) 0.12%
Owned by Institutions (%) 98.46%
Shares Floating 24.37M
Failed to Deliver (FTD) Shares 5.71K
FTD / Avg. Volume 1.39%

Short Selling Information

The latest short interest is 5.04M, so 18.62% of the outstanding shares have been sold short.

Short Interest 5.04M
Short % of Shares Out 18.62%
Short % of Float 20.52%
Short Ratio (days to cover) 11.98

Valuation Ratios

The PE ratio is -5.66 and the forward PE ratio is -11.04. Arcturus Therapeutics's PEG ratio is -0.03.

PE Ratio -5.66
Forward PE -11.04
PS Ratio 3.01
Forward PS 0.3
PB Ratio 1.9
P/FCF Ratio -7.59
PEG Ratio -0.03
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Arcturus Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 4.67, with a Debt / Equity ratio of 0.1.

Current Ratio 4.67
Quick Ratio 4.67
Debt / Equity 0.1
Debt / EBITDA -0.32
Debt / FCF -0.41
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $875.34K
Profits Per Employee $-465.18K
Employee Count 174
Asset Turnover 0.44
Inventory Turnover n/a

Taxes

Income Tax -4K
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -70.73% in the last 52 weeks. The beta is 2.96, so Arcturus Therapeutics's price volatility has been higher than the market average.

Beta 2.96
52-Week Price Change -70.73%
50-Day Moving Average 15.31
200-Day Moving Average 19.17
Relative Strength Index (RSI) 22.4
Average Volume (20 Days) 412.07K

Income Statement

In the last 12 months, Arcturus Therapeutics had revenue of 152.31M and earned -80.94M in profits. Earnings per share was -3.

Revenue 152.31M
Gross Profit 152.31M
Operating Income -95.67M
Net Income -80.94M
EBITDA -77.4M
EBIT -80.94M
Earnings Per Share (EPS) -3
Full Income Statement

Balance Sheet

The company has 237.03M in cash and 25M in debt, giving a net cash position of 212.03M.

Cash & Cash Equivalents 237.03M
Total Debt 25M
Net Cash 212.03M
Retained Earnings -448.81M
Total Assets 344.07M
Working Capital 240.49M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -59.75M and capital expenditures -648K, giving a free cash flow of -60.4M.

Operating Cash Flow -59.75M
Capital Expenditures -648K
Free Cash Flow -60.4M
FCF Per Share -2.24
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -62.81% and -53.14%.

Gross Margin 100%
Operating Margin -62.81%
Pretax Margin -53.14%
Profit Margin -53.14%
EBITDA Margin -50.82%
EBIT Margin -62.81%
FCF Margin -39.65%

Dividends & Yields

ARCT does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for ARCT is $60, which is 536.3% higher than the current price. The consensus rating is "Buy".

Price Target $60
Price Target Difference 536.3%
Analyst Consensus Buy
Analyst Count 6
Stock Forecasts

Stock Splits

The last stock split was on Nov 16, 2017. It was a backward split with a ratio of 1:7.

Last Split Date Nov 16, 2017
Split Type backward
Split Ratio 1:7

Scores

Altman Z-Score 0.2
Piotroski F-Score 3